---
title: "SION Investors Have Opportunity to Join Sionna Therapeutics, Inc. Fraud Investigation with SBS Law"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296031680.md"
description: "Schall, Brown & Schwartz LLP is investigating Sionna Therapeutics (NASDAQ: SION) for potential securities law violations. The probe examines whether the company issued misleading statements or failed to disclose material information regarding its SION-719 Phase 2a trial results announced on August 10, 2026. Following the announcement that the trial missed key endpoints, Sionna's shares plummeted over 91%. Investors who suffered losses are encouraged to contact the firm to discuss their rights and potentially join the investigation."
datetime: "2026-08-16T21:31:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296031680.md)
  - [en](https://longbridge.com/en/news/296031680.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296031680.md)
generator: "portal-rs"
---

# SION Investors Have Opportunity to Join Sionna Therapeutics, Inc. Fraud Investigation with SBS Law

**SION Investors Have Opportunity to Join Sionna Therapeutics, Inc. Fraud Investigation with SBS Law**

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sionna Therapeutics, Inc. (“Sionna” or “the Company”) (NASDAQ: SION) for violations of the securities laws. 

**INVESTIGATION DETAILS:** The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Sionna announced on August 10, 2026, that the “SION-719 Phase 2a proof-of-concept trial did not achieve key activity endpoint of sweat chloride reduction when added to standard of care.” Based on this news, shares of Sionna fell by more than 91%. 

If you are a shareholder who suffered a loss, click here to participate. 

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at david@schallfirm.com 

**WHY SBS?** Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor. 

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. 

Schall, Brown & Schwartz LLP  
Brian Schall, Esq.,  
Andrew Brown, Esq.,  
David Schwartz, Esq.,  
www.schallfirm.com  
Office: 310-301-3335  
info@schallfirm.com 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260816573556/en/

### Related Stocks

- [SION.US](https://longbridge.com/en/quote/SION.US.md)

## Related News & Research

- [22:22 ETRobbins LLP Reminds Stockholders it is Investigating the Recent Stock Drop of Sionna Therapeutics](https://longbridge.com/en/news/296425061.md)
- [Robbins LLP is Investigating the Recent Stock Drop of Sionna Therapeutics; Contact the Firm for Information](https://longbridge.com/en/news/296143993.md)
- [TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law](https://longbridge.com/en/news/296031849.md)
- [UI Investors Have Opportunity to Join Ubiquiti Inc. Fraud Investigation with SBS Law](https://longbridge.com/en/news/296246638.md)
- [JBTM Investors Have Opportunity to Join JBT Marel Corporation Fraud Investigation with SBS Law](https://longbridge.com/en/news/296136950.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**